The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.
Jim Cramer breaks down the slowing job growth in once robust industries.
This small drug company loses half of its value. See why.
With 38 million Americans suffering from migraines, the FDA's approval of Eli Lilly's preventative migraine drug Emgality can help them get their lives back. We spoke with Christi Shaw, president, Lilly Bio-Medicines for all the details.
Cannabidiol, or CBD, is a cannabis extract that's used to treat everything from pain to opiate addiction to PTSD. It doesn't get you high -- but advocates say that's the reason that CBD could soon eclipse the multibillion-dollar pot industry.
See what this little known veteran of a company has in store in the animal health industry.
The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.
Does the smoking cannabis industry share more than a few things in common with the Dot-com in the 1990s. Check out this podcast from the Real Money team.
Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.